Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Novartis Ireland Ltd regarding Beovu® (brolucizumab): Updated recommendations to minimise the known risk of intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion
Important Safety Information – Beovu (brolucizumab)